Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656097 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects
A Phase 2 study, sponsored by Crucell Holland.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT00656097: Completed Phase 2 study, sponsored by Crucell Holland.
NCT00656097 is a Phase 2 study that has completed, run by Crucell Holland. The registered enrollment target is 140 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00656097, a Phase 2 study, has completed, sponsored by Crucell Holland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) or placebo in combination with rabies vaccine in healthy adult subjects.
Interventions
- BIOLOGICAL CL184
- BIOLOGICAL HRIG
- BIOLOGICAL Placebo matching CL184
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00656097
The ClinicalTrials.gov registry entry for NCT00656097 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crucell Holland, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CL184 is the first listed.
NCT00656097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00656097 about?
NCT00656097 is a clinical study titled "A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects". The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) or placebo in combination with rabies vaccine in healthy adult subjects.
What is the current status of trial NCT00656097?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2008-03. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00656097?
The interventions under investigation include: CL184 (BIOLOGICAL), HRIG (BIOLOGICAL), Placebo matching CL184 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00656097?
This trial is sponsored by Crucell Holland, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.